Sartorius Stedim Biotech acquires majority stake in U.S. start-up AllPure Technologies

  • Takeover extends Sartorius Stedim Biotech portfolio for single-use bioprocessing

AUBAGNE, France--()--Regulatory News:

Sartorius Stedim Biotech (SSB)(Paris:DIM), a leading international supplier for the pharmaceutical and biotech industries, announced that it has signed a contract to acquire the majority stake in the U.S. start-up AllPure Technologies LLC. The privately owned company based in New Oxford, Pennsylvania, USA, has been operating on the market for four years, and in 2013 earned revenue of around U.S. $3 million with 25 employees. AllPure specializes in innovative single-use components for biopharmaceutical applications, such as aseptic sampling techniques. The parties agreed not to disclose any further details of the purchase agreement.

Reinhard Vogt, member of SSB’s Executive Board commented: “AllPure further completes our portfolio with innovative products that help our customers develop and manufacture their pharmaceutical drugs safer and more efficiently. I am really looking forward to working with the AllPure team and to all that we can accomplish together.”

“We are excited to leverage Sartorius Stedim’s impressive R&D capabilities so that we can accelerate the launch of new products from AllPure. And SSB’s global reach and industry relationships grant access to considerably more customers, especially in Europe and Asia, which have tremendous potential for AllPure’s products,” said Michael Zumbrum, President of AllPure.

Profile of Sartorius Stedim Biotech

Sartorius Stedim Biotech is a leading provider of cutting-edge equipment and services for the development, quality assurance and production processes of the biopharmaceutical industry. Its integrated solutions covering fermentation, cell cultivation, filtration, purification, fluid management and lab technologies are supporting the biopharmaceutical industry around the world to develop and produce drugs safely, timely and economically. Sartorius Stedim Biotech focuses on single-use technologies and value-added services to meet the rapidly changing technology requirements of the industry it serves. Strongly rooted in the scientific community and closely allied with customers and technology partners, the company is dedicated to its philosophy of “turning science into solutions.”

Headquartered in Aubagne, France, Sartorius Stedim Biotech is listed on the Eurolist of Euronext Paris. With its own manufacturing and R&D sites in Europe, North America and Asia and a global network of sales companies, Sartorius Stedim Biotech enjoys a worldwide presence. Its key manufacturing and R&D site is in Germany. The company employs approx. 3,300 people, and in 2013 earned sales revenue of 588.4 million euros.

Contacts

Sartorius Stedim Biotech
Petra Kirchhoff, +49(0)551-308-1686
Vice President of Corporate Communications
petra.kirchhoff@sartorius.com

Sharing

Contacts

Sartorius Stedim Biotech
Petra Kirchhoff, +49(0)551-308-1686
Vice President of Corporate Communications
petra.kirchhoff@sartorius.com